홈 > 시장보고서 > 의료기기 > 체외진단

시장보고서

상품코드

1324831

폐암 검진 시장 규모 및 예측(-2030년) - 암종, 기술, 연령대, 최종사용자별 세계 분석

Lung Cancer Screening Market Size and Forecast to 2030 - Global Analysis by Cancer Type, Technology, Age Group (50 & Older and Below 50), and End User (Hospitals, Diagnostic Centers, and Others)

발행일: 2023년 07월 | 리서치사:

The Insight Partners | 페이지 정보: 영문 188 Pages | 배송안내 : 즉시배송

※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문 목차를 참고해주시기 바랍니다.

폐암 검진 시장 규모는 2022년 23억 2,650만 달러에서 2030년 43억 6,395만 달러로 성장할 것으로 예상되며, 2022년부터 2030년까지 8.2%의 CAGR을 기록할 것으로 추정됩니다.

폐암 검진 시장의 성장은 폐암 발병률 증가와 정부 지원 증가에 기인합니다. 그러나 폐암 검진의 높은 검사비용은 폐암 검진 시장의 성장을 저해하고 있습니다.

폐암 검진은 폐암 위험이 높은 건강한 사람에게서 폐암을 발견하는 과정입니다. 폐암 검진은 폐암의 징후나 증상이 없는 고령자 중 오랜 기간 흡연한 사람에게 권장됩니다. 의사는 폐의 LDCT 스캔을 통해 폐암을 검사합니다. 폐암을 조기에 발견하면 치료로 완치될 가능성이 높아집니다.

정부 지원 확대에 따른 폐암 검진 시장 성장 촉진

미국 예방 서비스 전문위원회는 55-80세, 흡연 경력 30년(하루 20개비씩 30년 동안 담배를 피운 것과 같음), 현재 담배를 피우고 있거나 지난 15년 이내에 금연한 사람이라면 매년 1회 저선량 컴퓨터단층촬영(LDCT) 폐암 검진을 받을 것을 권고하고 있습니다. 권고하고 있습니다.

Cancer Australia 2023 보고서에 따르면 폐암은 호주에서 가장 흔한 암으로 사망률의 대부분을 차지합니다. 또한 폐암을 조기에 발견하면 생존율을 높일 수 있습니다. 또한 새로운 검진 프로그램은 성공적인 치료가 어려운 초기 단계에서 폐암을 발견하는 데 도움이 될 수 있습니다. 예를 들어, 2021년 7월, 캔서 호주는 호주에서 폐암 검진 프로그램의 타당성을 판단하기 위해 호주 보건 및 노인 의료부와 협력했습니다.

이러한 정부 지원과 정책, 여러 정부의 승인은 폐암 검진 시장의 성장을 촉진하고 있습니다.

폐암 검진 시장 - 암 유형별 인사이트

폐암 검진 시장은 암 유형에 따라 비소세포폐암과 소세포폐암으로 구분되며, 비소세포폐암 부문은 2022년 가장 큰 시장 점유율을 차지할 것으로 예상되며 예측 기간 동안 CAGR 10.3%로 성장할 것으로 예상됩니다. 이 부문의 시장 지위는 전 세계적으로 비소세포폐암 사례가 증가하고 있으며, 비소세포폐암은 소세포폐암보다 발병이 느리고, 비소세포폐암은 일반적으로 진단을 받기 전에 환자의 신체의 다른 부위로 전이됩니다. 따라서 조기 진단과 조기 치료가 중요합니다. 미국 암 연구 재단에 따르면 비소세포폐암은 10명 중 9명꼴로 발생합니다. 이 소식통에 따르면 대세포 미분화암 폐암은 전체 비소세포폐암 진단의 약 10-15%를 차지합니다.

폐암 검진 시장 - 기술적 인사이트

기술에 따라 폐암 검진 시장은 LDCT, 흉부 엑스레이, 액체 생검 및 기타로 구분되며, LDCT는 2022년 가장 큰 시장 점유율을 차지할 것으로 예상되며 예측 기간 동안 CAGR 8.0%로 성장할 것으로 예상됩니다.

폐암 검진 시장 - 연령대별 인사이트

연령대별로 폐암 검진 시장은 50세 이상과 50세 미만으로 구분되며, 50세 이상 부문이 2022년 가장 큰 시장 점유율을 차지했고, 50세 미만 부문은 예측 기간 동안 8.9%의 CAGR로 성장할 것으로 예상됩니다.

폐암 검진 시장 - 최종사용자별 인사이트

최종사용자에 따라 폐암 검진 시장은 병원, 진단 센터, 기타로 분류됩니다. 병원 부문이 2022년 가장 큰 시장 점유율을 차지했으며, 기타 부문은 예측 기간 동안 CAGR 8.7%로 성장할 것으로 예상됩니다.

폐암 검진 시장 - 최근 시장 개척:

폐암 검진 시장에서는 M&A와 같은 무기 및 유기적 전략이 기업들에 의해 고도로 채택되고 있습니다. 최근 몇 가지 주요 시장 개척을 살펴보면 다음과 같습니다.

지난 11월, GE헬스케어와 옵텔럼은 폐암의 정밀 진단과 치료를 촉진하기 위해 파트너십을 체결했습니다. 양사는 폐암 진단의 가장 큰 난제 중 하나인 폐결절(양성 또는 암으로 의심되는 병변)의 악성도를 의료진이 판단할 수 있도록 하기 위해 협력하고 있습니다.

로얄 필립스는 2022년 6월 바이오데식스(Biodesix)와 파트너십을 맺고 바이오데식스의 혈액 기반 폐결절 위험도 평가 검사 Nodify Lung의 결과를 필립스의 폐암 환자 관리 시스템인 폐암 오케스트레이터(Lung Cancer Orchestrator)에 통합했습니다. 현재 치료 방침을 결정하는 데 사용되는 방사선 및 환자 병력 데이터와 함께 폐암 오케스트레이터 내 바이오데식스 노디파이 렁 애플리케이션을 통해 프로테오믹스 데이터는 폐암 오케스트레이터의 컨텍스트 실행을 통해 늘어나는 폐결절 사례 관리 암 의료 센터의 진단 효율을 높이는 데 도움이 됩니다.

2021년 5월, Genetron Holdings Limited는 중국 의료기기 박람회에서 지멘스 헬스니어스(Siemens Healthineers)와 제휴를 맺었습니다. 이번 제휴는 비소세포폐암(NSCLC) 환자에게 효율적이고 정확한 개별화 진단 및 치료 지침을 제공하기 위해 중국 병원에서 Genetron의 S5 플랫폼과 폐암 8유전자 IVD 분석의 대규모 적용을 촉진하는 것을 목표로 하고 있습니다.

Lung cancer screening is a process used to detect lung cancer in otherwise healthy people with a high risk of lung cancer. Lung cancer screening is recommended for older adults who are long time smokers and who don't have any signs or symptoms of lung cancer. Doctors use a LDCT scan of the lungs to look for lung cancer. If lung cancer is detected early, it's more likely to be cured with treatment.

Rising Government Supportis Boosting The Growth Of The Lung Cancer Screening Market

The United States Preventive Services Task Force recommends people aged 55-80 with a 30-pack-year (equivalent to smoking 20 cigarettes per day for 30 years) smoking history who are presently smoking or have quit within the last 15 years to undergo annual low-dose computed tomography (LDCT) screening for lung cancer.

As per the Cancer Australia 2023 report, lung cancer is the most common form of cancer in Australia, accounting for the majority of the mortality rates. Furthermore, early detection of lung cancer helps improve survival rates. Also, the new screening program will help detect lung cancer during the early stages when treatment is not likely to be successful. For example, in July 2021, Cancer Australia partnered with the Department of Health and Aged Care to determine the feasibility of a lung cancer screening program in Australia.

Such rising government support, policies, and approvals by several governments are boosting the growth of the lung cancer screening market.

Lung Cancer Screening Market - Cancer Type Insights

Based on cancer type, the lung cancer screening market is bifurcated into NSCLC and small cell lung cancer. The NSCLC segment accounted for the largest market share in 2022 and is expected to grow at a CAGR of 10.3% during the forecast period. The market position of this segment is due to the rising cases of NSCLC over the globe. NSCLC develops more slowly than small cell lung cancer. It usually spreads to other parts of the patient's body by the time it is diagnosed. Therefore, early diagnosis and treatment are crucial. According to National Foundation for Cancer Research, NSCLC accounts for nearly 9 out of every 10 diagnoses. As per the same source, large-cell undifferentiated carcinoma lung cancer accounts for approximately 10-15% of all NSCLC diagnoses.

Lung Cancer Screening Market - Technology Insights

Based on technology, the Lung cancer screening market is segmented into LDCT, chest X-ray, liquid biopsy, and others. The LDCT accounted for the largest market share in 2022 and same is expected to grow at a CAGR of 8.0% during the forecast period.

Lung Cancer Screening Market - Age Group Insights

Based on age group, the lung cancer screening market is bifurcated into 50 & older and below 50. The 50 & older segment accounted for the largest market share in 2022, however, the below 50 is expected to grow at a CAGR of 8.9% during the forecast period.

Lung Cancer Screening Market - End User Insights

Based on end user, the lung cancer screening market is segmented into hospitals, diagnostic centers, and others. The hospitals segment accounted for the largest market share in 2022, however, the others is expected to grow at a CAGR of 8.7% during the forecast period.

Lung Cancer Screening Market - Recent Developments:

Inorganic and organic strategies such as mergers and acquisitions are highly adopted by companies in the lung cancer screening market. A few recent key market developments are listed below:

In November 2021, GE Healthcare and Optellum collaborated to advance precision diagnosis and treatment of lung cancer. Together, the companies are seeking to address one of the largest challenges in diagnosing lung cancer, helping providers to determine the malignancy of a lung nodule: a suspicious lesion that may be benign or cancerous.

In June 2022, Royal Philips teamed up with Biodesix, Inc. to incorporate the results of Biodesix's Nodify Lung blood-based lung nodule risk assessment testing into Philips Lung Cancer Orchestrator lung cancer patient management system. The incorporation of proteomics data - along with the radiologic and patient history data currently used to determine treatment decisions can help create diagnostic efficiency for cancer care centers in the management of a growing number of lung nodule cases via the contextual launch of Biodesix Nodify Lung application within Lung Cancer Orchestrator.

In May 2021, Genetron Holdings Limited has partnered with Siemens Healthineers at the China Medical Equipment Fair. This partnership aims to promote the large-scale application of Genetron's S5 platform and lung cancer 8-gene IVD assay in Chinese hospitals to provide non-small cell lung cancer (NSCLC) patients with efficient and accurate personalized diagnosis and treatment guidance.

Reasons to Buy:

Save and reduce time carrying out entry-level research by identifying the growth, size, leading players, and segments in the lung cancer screening market.
Highlights key business priorities in order to assist companies to realign their business strategies.
The key findings and recommendations highlight crucial progressive industry trends in the lung cancer screening market, thereby allowing players across the value chain to develop effective long-term strategies.
Develop/modify business expansion plans by using substantial growth offering developed and emerging markets.
Scrutinize in-depth global market trends and outlook coupled with the factors driving the market, as well as those hindering it.
Enhance the decision-making process by understanding the strategies that underpin security interest with respect to client products, segmentation, pricing and distribution.

1. Introduction

1.1 Study Scope
1.2 The Insight Partners Research Report Guidance
1.3 Market Segmentation
- 1.3.1 Global Lung Cancer Screening Market - by Technology
- 1.3.2 Global Lung Cancer Screening Market - by Cancer Type
- 1.3.3 Global Lung Cancer Screening Market - by Age Group
- 1.3.4 Global Lung Cancer Screening Market - by End User
- 1.3.5 Global Lung Cancer Screening Market - by Geography

2. Lung Cancer Screening Market - Key Takeaways

3. Research Methodology

3.1 Coverage
3.2 Secondary Research
3.3 Primary Research

4. Lung Cancer Screening Market - Market Landscape

4.1 Overview
4.2 PEST Analysis
- 4.2.1 North America PEST Analysis
- 4.2.2 Europe PEST Analysis
- 4.2.3 Asia Pacific PEST Analysis
- 4.2.4 South & Central America PEST Analysis
- 4.2.5 Middle East & Africa PEST Analysis
4.3 Expert's Opinion

5. Lung Cancer Screening Market - Key Market Dynamics

5.1 Market Drivers
- 5.1.1 Rising Lung Cancer Incidences
- 5.1.2 Increasing Government Support
5.2 Market Restraints
- 5.2.1 High Cost of Lung Cancer Screening Tests
5.3 Market Opportunities
- 5.3.1 Structured Lung Cancer Screening Program
5.4 Future Trends
- 5.4.1 Mobile Lung Cancer Screening Truck
5.5 Impact Analysis

6. Lung Cancer Screening Market - Global Analysis

6.1 Global Lung Cancer Screening Market Revenue Forecast and Analysis
6.2 Global Lung Cancer Screening Market, by Geography - Forecast and Analysis

7. Global Lung Cancer Screening Market - Revenue and Forecast to 2028 - By Cancer Type

7.1 Overview
7.2 Lung Cancer Screening Market Revenue Share, by Cancer Type 2022 & 2030 (%)
7.3 Non-Small Cell Lung Cancer (NSCLC)
- 7.3.1 Overview
- 7.3.2 Non-Small Cell Lung Cancer (NSCLC): Lung Cancer Screening Market - Revenue and Forecast to 2030 (US$ Mn)
7.4 Small Cell Lung Cancer
- 7.4.1 Overview
- 7.4.2 Small Cell Lung Cancer: Lung Cancer Screening Market - Revenue and Forecast to 2030 (US$ Million)

8. Lung Cancer Screening Market Analysis - by Technology

8.1 Overview
8.2 Low-Dose Computed Tomography (LDCT)
- 8.2.1 Overview
- 8.2.2 Low-Dose Computed Tomography (LDCT): Lung Cancer Screening Market- Revenue and Forecast to 2030 (US$ Million)
8.3 Chest X-ray
- 8.3.1 Overview
- 8.3.2 Chest X-ray: Lung Cancer Screening Market- Revenue and Forecast to 2030 (US$ Million)
8.4 Liquid Biopsy
- 8.4.1 Overview
- 8.4.2 Liquid Biopsy: Lung Cancer Screening Market- Revenue and Forecast to 2030 (US$ Million)
8.5 Others
- 8.5.1 Overview
- 8.5.2 Others: Lung Cancer Screening Market- Revenue and Forecast to 2030 (US$ Million)

9. Lung Cancer Screening Market Analysis - by Age Group

9.1 Overview
9.2 & Older
- 9.2.1 Overview
- 9.2.2 & Older: Australia Lung Cancer Screenings Market - Revenue and Forecast to 2030 (US$ Million)
9.3 Below 50
- 9.3.1 Overview
- 9.3.2 Below 50: Lung Cancer Screenings Market - Revenue and Forecast to 2030 (US$ Million)

10. Lung Cancer Screening Market Analysis - by End User

10.1 Overview
10.2 Hospitals
- 10.2.1 Overview
- 10.2.2 Hospitals: Lung Cancer Screenings Market - Revenue and Forecast to 2030 (US$ Million)
10.3 Diagnostic Centers
- 10.3.1 Overview
- 10.3.2 Diagnostic Centers: Lung Cancer Screenings Market - Revenue and Forecast to 2030 (US$ Million)
10.4 Others
- 10.4.1 Overview
- 10.4.2 Others: Lung Cancer Screenings Market - Revenue and Forecast to 2030 (US$ Million)

11. Lung Cancer Screening Market - Revenue and Forecast to 2028 - Geographic Analysis

11.1 North America: Lung Cancer Screening Market
- 11.1.1 Overview
- 11.1.2 North America: Lung Cancer Screening Market - Revenue and Forecast to 2030 (US$ Million)
- 11.1.3 North America: Lung Cancer Screening Market, by Cancer Type, 2020-2030 (US$ Million)
- 11.1.4 North America: Lung Cancer Screening Market, by Technology - 2020-2030 (US$ Million)
- 11.1.5 North America: Lung Cancer Screening Market, by Age Group, 2020-2030 (US$ Million)
- 11.1.6 North America: Lung Cancer Screening Market, by End User, 2020-2030 (US$ Million)
  - 11.1.6.1 US: Lung Cancer Screening Market - Revenue and Forecast to 2030 (US$ Million)
    - 11.1.6.1.1 Overview
    - 11.1.6.1.2 US: Lung Cancer Screening Market - Revenue and Forecast to 2030 (US$ Million)
    - 11.1.6.1.3 US: Lung Cancer Screening Market, by Cancer Type, 2020-2030 (US$ Million)
    - 11.1.6.1.4 US: Lung Cancer Screening Market, by Technology - Revenue and Forecast to 2030 (US$ Million)
    - 11.1.6.1.5 US: Lung Cancer Screening Market, by Age Group, 2020-2030 (US$ Million)
    - 11.1.6.1.6 US: Lung Cancer Screening Market, by End User, 2020-2030 (US$ Million)
  - 11.1.6.2 Canada: Lung Cancer Screening Market - Revenue and Forecast to 2030 (US$ Million)
    - 11.1.6.2.1 Overview
    - 11.1.6.2.2 Canada: Lung Cancer Screening Market - Revenue and Forecast to 2030 (US$ Million)
    - 11.1.6.2.3 Canada: Lung Cancer Screening Market, by Cancer Type, 2020-2030 (US$ Million)
    - 11.1.6.2.4 Canada: Lung Cancer Screening Market, by Technology - Revenue and Forecast to 2030 (US$ Million)
    - 11.1.6.2.5 Canada: Lung Cancer Screening Market, by Age Group, 2020-2030 (US$ Million)
    - 11.1.6.2.6 Canada: Lung Cancer Screening Market, by End User, 2020-2030 (US$ Million)
  - 11.1.6.3 Mexico: Lung Cancer Screening Market - Revenue and Forecast to 2030 (US$ Million)
    - 11.1.6.3.1 Overview
    - 11.1.6.3.2 Mexico: Lung Cancer Screening Market - Revenue and Forecast to 2030 (US$ Million)
    - 11.1.6.3.3 Mexico: Lung Cancer Screening Market, by Cancer Type, 2020-2030 (US$ Million)
    - 11.1.6.3.4 Mexico: Lung Cancer Screening Market, by Technology - Revenue and Forecast to 2030 (US$ Million)
    - 11.1.6.3.5 Mexico: Lung Cancer Screening Market, by Age Group, 2020-2030 (US$ Million)
    - 11.1.6.3.6 Mexico: Lung Cancer Screening Market, by End User, 2020-2030 (US$ Million)
11.2 Europe: Lung Cancer Screening Market
- 11.2.1 Overview
- 11.2.2 Europe: Lung Cancer Screening Market - Revenue and Forecast to 2030 (US$ Million)
- 11.2.3 Europe: Lung Cancer Screening Market, by Cancer Type, 2020-2030 (US$ Million)
- 11.2.4 Europe: Lung Cancer Screening Market, by Technology - 2020-2030 (US$ Million)
- 11.2.5 Europe: Lung Cancer Screening Market, by Age Group, 2020-2030 (US$ Million)
- 11.2.6 Europe: Lung Cancer Screening Market, by End User, 2020-2030 (US$ Million)
  - 11.2.6.1 Germany: Lung Cancer Screening Market - Revenue and Forecast to 2030 (US$ Million)
    - 11.2.6.1.1 Overview
    - 11.2.6.1.2 Germany: Lung Cancer Screening Market - Revenue and Forecast to 2030 (US$ Million)
    - 11.2.6.1.3 Germany: Lung Cancer Screening Market, by Cancer Type, 2020-2030 (US$ Million)
    - 11.2.6.1.4 Germany: Lung Cancer Screening Market, by Technology - Revenue and Forecast to 2030 (US$ Million)
    - 11.2.6.1.5 Germany: Lung Cancer Screening Market, by Age Group, 2020-2030 (US$ Million)
    - 11.2.6.1.6 Germany: Lung Cancer Screening Market, by End User, 2020-2030 (US$ Million)
  - 11.2.6.2 UK: Lung Cancer Screening Market - Revenue and Forecast to 2030 (US$ Million)
    - 11.2.6.2.1 Overview
    - 11.2.6.2.2 UK: Lung Cancer Screening Market - Revenue and Forecast to 2030 (US$ Million)
    - 11.2.6.2.3 UK: Lung Cancer Screening Market, by Cancer Type, 2020-2030 (US$ Million)
    - 11.2.6.2.4 UK: Lung Cancer Screening Market, by Technology - Revenue and Forecast to 2030 (US$ Million)
    - 11.2.6.2.5 UK: Lung Cancer Screening Market, by Age Group, 2020-2030 (US$ Million)
    - 11.2.6.2.6 UK: Lung Cancer Screening Market, by End User, 2020-2030 (US$ Million)
  - 11.2.6.3 France: Lung Cancer Screening Market - Revenue and Forecast to 2030 (US$ Million)
    - 11.2.6.3.1 Overview
    - 11.2.6.3.2 France: Lung Cancer Screening Market - Revenue and Forecast to 2030 (US$ Million)
    - 11.2.6.3.3 France: Lung Cancer Screening Market, by Cancer Type, 2020-2030 (US$ Million)
    - 11.2.6.3.4 France: Lung Cancer Screening Market, by Technology - Revenue and Forecast to 2030 (US$ Million)
    - 11.2.6.3.5 France: Lung Cancer Screening Market, by Age Group, 2020-2030 (US$ Million)
    - 11.2.6.3.6 France: Lung Cancer Screening Market, by End User, 2020-2030 (US$ Million)
  - 11.2.6.4 Italy: Lung Cancer Screening Market - Revenue and Forecast to 2030 (US$ Million)
    - 11.2.6.4.1 Overview
    - 11.2.6.4.2 Italy: Lung Cancer Screening Market - Revenue and Forecast to 2030 (US$ Million)
    - 11.2.6.4.3 Italy: Lung Cancer Screening Market, by Cancer Type, 2020-2030 (US$ Million)
    - 11.2.6.4.4 Italy: Lung Cancer Screening Market, by Technology - Revenue and Forecast to 2030 (US$ Million)
    - 11.2.6.4.5 Italy: Lung Cancer Screening Market, by Age Group, 2020-2030 (US$ Million)
    - 11.2.6.4.6 Italy: Lung Cancer Screening Market, by End User, 2020-2030 (US$ Million)
  - 11.2.6.5 Spain: Lung Cancer Screening Market - Revenue and Forecast to 2030 (US$ Million)
    - 11.2.6.5.1 Overview
    - 11.2.6.5.2 Spain: Lung Cancer Screening Market - Revenue and Forecast to 2030 (US$ Million)
    - 11.2.6.5.3 Spain: Lung Cancer Screening Market, by Cancer Type, 2020-2030 (US$ Million)
    - 11.2.6.5.4 Spain: Lung Cancer Screening Market, by Technology - Revenue and Forecast to 2030 (US$ Million)
    - 11.2.6.5.5 Spain: Lung Cancer Screening Market, by Age Group, 2020-2030 (US$ Million)
    - 11.2.6.5.6 Spain: Lung Cancer Screening Market, by End User, 2020-2030 (US$ Million)
  - 11.2.6.6 Rest of Europe: Lung Cancer Screening Market - Revenue and Forecast to 2030 (US$ Million)
    - 11.2.6.6.1 Overview
    - 11.2.6.6.2 Rest of Europe: Lung Cancer Screening Market - Revenue and Forecast to 2030 (US$ Million)
    - 11.2.6.6.3 Rest of Europe: Lung Cancer Screening Market, by Cancer Type, 2020-2030 (US$ Million)
    - 11.2.6.6.4 Rest of Europe: Lung Cancer Screening Market, by Technology - Revenue and Forecast to 2030 (US$ Million)
    - 11.2.6.6.5 Rest of Europe: Lung Cancer Screening Market, by Age Group, 2020-2030 (US$ Million)
    - 11.2.6.6.6 Rest of Europe: Lung Cancer Screening Market, by End User, 2020-2030 (US$ Million)
11.3 Asia-Pacific: Lung Cancer Screening Market
- 11.3.1 Overview
- 11.3.2 Asia Pacific: Lung Cancer Screening Market - Revenue and Forecast to 2030 (US$ Million)
- 11.3.3 Asia Pacific: Lung Cancer Screening Market, by Cancer Type, 2020-2030 (US$ Million)
- 11.3.4 Asia Pacific: Lung Cancer Screening Market, by Technology - 2020-2030 (US$ Million)
- 11.3.5 Asia Pacific: Lung Cancer Screening Market, by Age Group, 2020-2030 (US$ Million)
- 11.3.6 Asia Pacific: Lung Cancer Screening Market, by End User, 2020-2030 (US$ Million)
  - 11.3.6.1 China: Lung Cancer Screening Market - Revenue and Forecast to 2030 (US$ Million)
    - 11.3.6.1.1 Overview
    - 11.3.6.1.2 China: Lung Cancer Screening Market - Revenue and Forecast to 2030 (US$ Million)
    - 11.3.6.1.3 China: Lung Cancer Screening Market, by Cancer Type, 2020-2030 (US$ Million)
    - 11.3.6.1.4 China: Lung Cancer Screening Market, by Technology - Revenue and Forecast to 2030 (US$ Million)
    - 11.3.6.1.5 China: Lung Cancer Screening Market, by Age Group, 2020-2030 (US$ Million)
    - 11.3.6.1.6 China: Lung Cancer Screening Market, by End User, 2020-2030 (US$ Million)
  - 11.3.6.2 Japan: Lung Cancer Screening Market - Revenue and Forecast to 2030 (US$ Million)
    - 11.3.6.2.1 Overview
    - 11.3.6.2.2 Japan: Lung Cancer Screening Market - Revenue and Forecast to 2030 (US$ Million)
    - 11.3.6.2.3 Japan: Lung Cancer Screening Market, by Cancer Type, 2020-2030 (US$ Million)
    - 11.3.6.2.4 Japan: Lung Cancer Screening Market, by Technology - Revenue and Forecast to 2030 (US$ Million)
    - 11.3.6.2.5 Japan: Lung Cancer Screening Market, by Age Group, 2020-2030 (US$ Million)
    - 11.3.6.2.6 Japan: Lung Cancer Screening Market, by End User, 2020-2030 (US$ Million)
  - 11.3.6.3 India: Lung Cancer Screening Market - Revenue and Forecast to 2030 (US$ Million)
    - 11.3.6.3.1 Overview
    - 11.3.6.3.2 India: Lung Cancer Screening Market - Revenue and Forecast to 2030 (US$ Million)
    - 11.3.6.3.3 India: Lung Cancer Screening Market, by Cancer Type, 2020-2030 (US$ Million)
    - 11.3.6.3.4 India: Lung Cancer Screening Market, by Technology - Revenue and Forecast to 2030 (US$ Million)
    - 11.3.6.3.5 India: Lung Cancer Screening Market, by Age Group, 2020-2030 (US$ Million)
    - 11.3.6.3.6 India: Lung Cancer Screening Market, by End User, 2020-2030 (US$ Million)
  - 11.3.6.4 Australia: Lung Cancer Screening Market - Revenue and Forecast to 2030 (US$ Million)
    - 11.3.6.4.1 Overview
    - 11.3.6.4.2 Australia: Lung Cancer Screening Market - Revenue and Forecast to 2030 (US$ Million)
    - 11.3.6.4.3 Australia: Lung Cancer Screening Market, by Cancer Type, 2020-2030 (US$ Million)
    - 11.3.6.4.4 Australia: Lung Cancer Screening Market, by Technology - Revenue and Forecast to 2030 (US$ Million)
    - 11.3.6.4.5 Australia: Lung Cancer Screening Market, by Age Group, 2020-2030 (US$ Million)
    - 11.3.6.4.6 Australia: Lung Cancer Screening Market, by End User, 2020-2030 (US$ Million)
  - 11.3.6.5 South Korea: Lung Cancer Screening Market - Revenue and Forecast to 2030 (US$ Million)
    - 11.3.6.5.1 Overview
    - 11.3.6.5.2 South Korea: Lung Cancer Screening Market - Revenue and Forecast to 2030 (US$ Million)
    - 11.3.6.5.3 South Korea: Lung Cancer Screening Market, by Cancer Type, 2020-2030 (US$ Million)
    - 11.3.6.5.4 South Korea: Lung Cancer Screening Market, by Technology - Revenue and Forecast to 2030 (US$ Million)
    - 11.3.6.5.5 South Korea: Lung Cancer Screening Market, by Age Group, 2020-2030 (US$ Million)
    - 11.3.6.5.6 South Korea: Lung Cancer Screening Market, by End User, 2020-2030 (US$ Million)
  - 11.3.6.6 Rest of Asia Pacific: Lung Cancer Screening Market - Revenue and Forecast to 2030 (US$ Million)
    - 11.3.6.6.1 Overview
    - 11.3.6.6.2 Rest of Asia Pacific: Lung Cancer Screening Market - Revenue and Forecast to 2030 (US$ Million)
    - 11.3.6.6.3 Rest of Asia Pacific: Lung Cancer Screening Market, by Cancer Type, 2020-2030 (US$ Million)
    - 11.3.6.6.4 Rest of Asia Pacific: Lung Cancer Screening Market, by Technology - Revenue and Forecast to 2030 (US$ Million)
    - 11.3.6.6.5 Rest of Asia Pacific: Lung Cancer Screening Market, by Age Group, 2020-2030 (US$ Million)
    - 11.3.6.6.6 Rest of Asia Pacific: Lung Cancer Screening Market, by End User, 2020-2030 (US$ Million)
11.4 Middle East & Africa: Lung Cancer Screening Market
- 11.4.1 Overview
- 11.4.2 Middle East & Africa: Lung Cancer Screening Market - Revenue and Forecast to 2030 (US$ Million)
- 11.4.3 Middle East & Africa: Lung Cancer Screening Market, by Cancer Type, 2020-2030 (US$ Million)
- 11.4.4 Middle East & Africa: Lung Cancer Screening Market, by Technology, 2020-2030 (US$ Million)
- 11.4.5 Middle East & Africa Lung Cancer Screening Market, by Age Group, 2020-2030 (US$ Million)
  - 11.4.5.2 South Africa: Lung Cancer Screening Market - Revenue and Forecast to 2030 (US$ Million)
    - 11.4.5.2.1 Overview
    - 11.4.5.2.2 South Africa: Lung Cancer Screening Market - Revenue and Forecast to 2030 (US$ Million)
    - 11.4.5.2.3 South Africa: Lung Cancer Screening Market, by Cancer Type, 2020-2030 (US$ Million)
    - 11.4.5.2.4 South Africa: Lung Cancer Screening Market, by Technology, 2020-2030 (US$ Million)
    - 11.4.5.2.5 South Africa Lung Cancer Screening Market, by Age Group, 2020-2030 (US$ Million)
    - 11.4.5.2.6 South Africa: Lung Cancer Screening Market, by End User, 2020-2030 (US$ Million)
  - 11.4.5.3 Saudi Arabia: Lung Cancer Screening Market - Revenue and Forecast to 2030 (US$ Million)
    - 11.4.5.3.1 Overview
    - 11.4.5.3.2 Saudi Arabia: Lung Cancer Screening Market - Revenue and Forecast to 2030 (US$ Million)
    - 11.4.5.3.3 Saudi Arabia: Lung Cancer Screening Market, by Cancer Type, 2020-2030 (US$ Million)
    - 11.4.5.3.4 Saudi Arabia: Lung Cancer Screening Market, by Technology, 2020-2030 (US$ Million)
    - 11.4.5.3.5 Saudi Arabia Lung Cancer Screening Market, by Age Group, 2020-2030 (US$ Million)
    - 11.4.5.3.6 Saudi Arabia: Lung Cancer Screening Market, by End User, 2020-2030 (US$ Million)
  - 11.4.5.4 UAE: Lung Cancer Screening Market - Revenue and Forecast to 2030 (US$ Million)
    - 11.4.5.4.1 Overview
    - 11.4.5.4.2 UAE: Lung Cancer Screening Market - Revenue and Forecast to 2030 (US$ Million)
    - 11.4.5.4.3 UAE: Lung Cancer Screening Market, by Cancer Type, 2020-2030 (US$ Million)
    - 11.4.5.4.4 UAE: Lung Cancer Screening Market, by Technology, 2020-2030 (US$ Million)
    - 11.4.5.4.5 UAE Lung Cancer Screening Market, by Age Group, 2020-2030 (US$ Million)
    - 11.4.5.4.6 UAE: Lung Cancer Screening Market, by End User, 2020-2030 (US$ Million)
  - 11.4.5.5 Rest of Middle East & Africa: Lung Cancer Screening Market - Revenue and Forecast to 2030 (US$ Million)
    - 11.4.5.5.1 Overview
    - 11.4.5.5.2 Rest of Middle East & Africa: Lung Cancer Screening Market - Revenue and Forecast to 2030 (US$ Million)
    - 11.4.5.5.3 Rest of Middle East & Africa: Lung Cancer Screening Market, by Cancer Type, 2020-2030 (US$ Million)
    - 11.4.5.5.4 Rest of Middle East & Africa: Lung Cancer Screening Market, by Technology, 2020-2030 (US$ Million)
    - 11.4.5.5.5 Rest of Middle East & Africa Lung Cancer Screening Market, by Age Group, 2020-2030 (US$ Million)
    - 11.4.5.5.6 Rest of Middle East & Africa: Lung Cancer Screening Market, by End User, 2020-2030 (US$ Million)
11.5 South & Central America: Lung Cancer Screening Market
- 11.5.1 Overview
- 11.5.2 South & Central America: Lung Cancer Screening Market - Revenue and Forecast to 2030 (US$ Million)
- 11.5.3 South & Central America: Lung Cancer Screening Market, by Cancer Type, 2020-2030 (US$ Million)
- 11.5.4 South & Central America: Lung Cancer Screening Market, by Technology - 2020-2030 (US$ Million)
- 11.5.5 South & Central America: Lung Cancer Screening Market, by Age Group, 2020-2030 (US$ Million)
- 11.5.6 South & Central America: Lung Cancer Screening Market, by End User, 2020-2030 (US$ Million)
  - 11.5.6.1 Brazil: Lung Cancer Screening Market - Revenue and Forecast to 2030 (US$ Million)
    - 11.5.6.1.1 Overview
    - 11.5.6.1.2 Brazil: Lung Cancer Screening Market - Revenue and Forecast to 2030 (US$ Million)
    - 11.5.6.1.3 Brazil: Lung Cancer Screening Market, by Cancer Type, 2020-2030 (US$ Million)
    - 11.5.6.1.4 Brazil: Lung Cancer Screening Market, by Technology - Revenue and Forecast to 2030 (US$ Million)
    - 11.5.6.1.5 Brazil: Lung Cancer Screening Market, by Age Group, 2020-2030 (US$ Million)
    - 11.5.6.1.6 Brazil: Lung Cancer Screening Market, by End User, 2020-2030 (US$ Million)
  - 11.5.6.2 Argentina: Lung Cancer Screening Market - Revenue and Forecast to 2030 (US$ Million)
    - 11.5.6.2.1 Overview
    - 11.5.6.2.2 Argentina: Lung Cancer Screening Market - Revenue and Forecast to 2030 (US$ Million)
    - 11.5.6.2.3 Argentina: Lung Cancer Screening Market, by Cancer Type, 2020-2030 (US$ Million)
    - 11.5.6.2.4 Argentina: Lung Cancer Screening Market, by Technology - Revenue and Forecast to 2030 (US$ Million)
    - 11.5.6.2.5 Argentina: Lung Cancer Screening Market, by Age Group, 2020-2030 (US$ Million)
    - 11.5.6.2.6 Argentina: Lung Cancer Screening Market, by End User, 2020-2030 (US$ Million)
  - 11.5.6.3 Rest of South & Central America: Lung Cancer Screening Market - Revenue and Forecast to 2030 (US$ Million)
    - 11.5.6.3.1 Overview
    - 11.5.6.3.2 Rest of South & Central America: Lung Cancer Screening Market - Revenue and Forecast to 2030 (US$ Million)
    - 11.5.6.3.3 Rest of South & Central America: Lung Cancer Screening Market, by Cancer Type, 2020-2030 (US$ Million)
    - 11.5.6.3.4 Rest of South & Central America: Lung Cancer Screening Market, by Technology - Revenue and Forecast to 2030 (US$ Million)
    - 11.5.6.3.5 Rest of South & Central America: Lung Cancer Screening Market, by Age Group, 2020-2030 (US$ Million)
    - 11.5.6.3.6 Rest of South & Central America: Lung Cancer Screening Market, by End User, 2020-2030 (US$ Million)

12. Pre and Post COVID-19 Impact on Lung Cancer Screening Market

12.1 Impact Analysis of COVID-19 Pandemic on Lung Cancer Screening Market

13. Lung Cancer Screening Market-Industry Landscape

13.1 Recent Growth Strategies
- 13.1.1 Overview

14. Company Profiles

14.1 Intelerad Medical Systems
- 14.1.1 Key Facts
- 14.1.2 Business Description
- 14.1.3 Products and Services
- 14.1.4 Financial Overview
- 14.1.5 SWOT Analysis
- 14.1.6 Key Developments
14.2 Nuance Communications Inc
- 14.2.1 Key Facts
- 14.2.2 Business Description
- 14.2.3 Products and Services
- 14.2.4 Financial Overview
- 14.2.5 SWOT Analysis
- 14.2.6 Key Developments
14.3 GE HealthCare
- 14.3.1 Key Facts
- 14.3.2 Business Description
- 14.3.3 Products and Services
- 14.3.4 Financial Overview
- 14.3.5 SWOT Analysis
- 14.3.6 Key Developments
14.4 Medtronic
- 14.4.1 Key Facts
- 14.4.2 Business Description
- 14.4.3 Products and Services
- 14.4.4 Financial Overview
- 14.4.5 SWOT Analysis
- 14.4.6 Key Developments
14.5 Canon Inc.
- 14.5.1 Key Facts
- 14.5.2 Business Description
- 14.5.3 Products and Services
- 14.5.4 Financial Overview
- 14.5.5 SWOT Analysis
- 14.5.6 Key Developments
14.6 Koninklijke Philips NV
- 14.6.1 Key Facts
- 14.6.2 Business Description
- 14.6.3 Products and Services
- 14.6.4 Financial Overview
- 14.6.5 SWOT Analysis
- 14.6.6 Key Developments
14.7 Siemens AG
- 14.7.1 Key Facts
- 14.7.2 Business Description
- 14.7.3 Products and Services
- 14.7.4 Financial Overview
- 14.7.5 SWOT Analysis
- 14.7.6 Key Developments
14.8 CVS Health
- 14.8.1 Key Facts
- 14.8.2 Business Description
- 14.8.3 Products and Services
- 14.8.4 Financial Overview
- 14.8.5 SWOT Analysis
- 14.8.6 Key Developments
14.9 bioAffinity Technologies, Inc.
- 14.9.1 Key Facts
- 14.9.2 Business Description
- 14.9.3 Products and Services
- 14.9.4 Financial Overview
- 14.9.5 SWOT Analysis
- 14.9.6 Key Developments
14.10 LungLife AI, Inc.
- 14.10.1 Key Facts
- 14.10.2 Business Description
- 14.10.3 Products and Services
- 14.10.4 Financial Overview
- 14.10.5 SWOT Analysis
- 14.10.6 Key Developments

15. Appendix

15.1 About The Insight Partners
15.2 Glossary of Terms

02-2025-2992
(주말 및 공휴일 제외)

라이선스 / 가격

PDF (Single User License)

PDF 보고서를 1명만 이용할 수 있는 라이선스입니다.

US $ 4,450

￦ 6,314,000

PDF (Site License)

PDF 보고서를 동일 사업장의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

US $ 6,450

￦ 9,153,000

PDF (Enterprise License)

PDF 보고서를 동일 기업의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

US $ 8,450

￦ 11,991,000

※ 부가세 별도

폐암 검진 시장 규모 및 예측(-2030년) - 암종, 기술, 연령대, 최종사용자별 세계 분석

Lung Cancer Screening Market Size and Forecast to 2030 - Global Analysis by Cancer Type, Technology, Age Group (50 & Older and Below 50), and End User (Hospitals, Diagnostic Centers, and Others)

목차

제1장 서론

제2장 폐암 검진 시장 - 요점

제3장 조사 방법

제4장 폐암 검진 시장 - 시장 상황

제5장 폐암 검진 시장 - 주요 시장 역학

제6장 폐암 검진 시장 - 세계 분석

제7장 폐암 검진 세계 시장 : 매출과 2028년까지 예측 : 암 유형별

제8장 폐암 검진 시장 분석 - 기술별

제9장 폐암 검진 시장 분석 : 연령층별

제10장 폐암 검진 시장 분석 - 최종사용자별

제11장 폐암 검진 시장 - 2028년까지 매출과 예측 - 지역별 시장 분석

제12장 COVID-19 전후 폐암 검진 시장에 대한 영향

제13장 폐암 검진 시장 - 업계 상황

제14장 기업 개요

제15장 기업 개요 부록